No Data
No Data
Disease activity improved by over 70%. johnson & johnson (JNJ.US) potential blockbuster monoclonal antibody recognized as a breakthrough therapy.
Johnson & Johnson (JNJ.US) announced recently that the US FDA has granted Breakthrough Therapy Designation (BTD) to its investigational antibody therapy nipocalimab targeting the neonatal Fc receptor (FcRn), for the treatment of adult patients with moderate to severe primary Sjögren's syndrome.
J&J Sues HHS Over 340B Hospital Drug-discount Program
Tuesday Market Finally Slows Down, Takes a Post Veterans Day Breather | Live Stock
3M, UnitedHealth Share Losses Lead Dow's 115-Point Drop
Express News | Johnson & Johnson Medtech Receives Ide Approval for Ottava™ Robotic Surgical System
Johnson & Johnson Today Announces That The U.S. FDA Has Granted Nipocalimab Breakthrough Therapy Designation For The Treatment Of Adults Living With Moderate-To-Severe Sjögren's Disease, A Debilitating And Chronic Autoantibody Disease With High...
Money Thrill : Very good overview and diversification